2005 (2005) Fair Value & Analysis

Healthcare · Market cap HK$6.4B

2 2005 2005 · HK

PriceHK$2.23

Fair ValueHK$2.92

Upside+30.9%

Quality48/100

Watch 2005 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$2.08 – HK$3.85

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −5.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$2.02 – HK$3.16 · fair‑value band HK$2.08 – HK$3.85 · the HK$2.23 price screens below the HK$2.92 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2005 (2005) currently trades at HK$2.23, while our model-based Fair Value estimate is HK$2.92 — implying the stock looks roughly 30.9% undervalued today. We read business quality at 48/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2005 generated revenue of HK$4.2B at a net margin of 11.3%. Revenue declined 17.1% year over year. It earns a return on equity of 6.4%. Net debt stands at HK$2.2B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$4.2B

Revenue growth (YoY) -17.1%

Net margin 11.3%

Return on equity 6.4%

Free cash flow HK$300M FY2025

P/E ratio 13.8

More key figures

Operating margin 11.1%

EPS (TTM) HK$0.1000

Dividend yield 3.8%

EPS growth (YoY) -49.5%

Net debt HK$2.2B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2005 reported revenue of HK$4.2B in FY2025 versus HK$5.4B in FY2021, a compound −6.1%/yr. Reported net income was HK$471M in FY2025, compounding −12.0%/yr from FY2021.

Revenue −6.1%/yr

FY21 HK$5.4B

FY22 HK$6.4B

FY23 HK$6.5B

FY24 HK$5.8B

FY25 HK$4.2B

Net income −12.0%/yr

FY21 HK$786M

FY22 HK$1.1B

FY23 HK$1.3B

FY24 HK$1.1B

FY25 HK$471M

Is 2005 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥49.36	¥30.99	-37%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$24.45	R$6.33	-74%
Hansoh Pharmaceutical Group 3692	HK$29.32	HK$23.94	-18%
Divi's Laboratories Limited DIVISLAB	₹6,623	₹1,461	-78%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2005 (2005) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$2.92 versus a price of HK$2.23 — about +31% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2005?

Our model-based fair value for 2005 is HK$2.92 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.23.

What is the quality score of 2005?

2005 has a Quality Score of 48/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2005 (2005)?

2005 reported trailing-twelve-month revenue of about HK$4.2B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2005?

The net profit margin of 2005 is about 11.3%, meaning it keeps roughly 11.3% of revenue as net income. Based on the latest reported figures.

Does 2005 pay a dividend?

2005 currently shows a dividend yield of about 3.77% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.